IGC Announces Issuance of Second Patent for the Treatment of Alzheimer's Using THCBusiness Wire • 09/21/22
IGC Acquires Exclusive Rights for a Potential Alzheimer's Drug Development CandidateBusiness Wire • 06/21/22
IGC Receives U.S. Patent for Method and Composition for Treating Seizure DisordersBusiness Wire • 06/09/22
India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action LawsuitsBusiness Wire • 04/18/22
India Globalization Capital Appoints Claudia Grimaldi to its Board of DirectorsBusiness Wire • 03/23/22
The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock - IGCPRNewsWire • 01/31/22
India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of DirectorsBusiness Wire • 01/19/22
Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New DrugBusiness Wire • 12/14/21
Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's PatientsBusiness Wire • 12/08/21
Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's PatientsBusiness Wire • 12/02/21
IGC Posts Q2 Results, Reveals Promising Results From Clinical Trial Of THC-Drug For Alzheimer's SymptomsBenzinga • 11/01/21
IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and TolerabilityBusiness Wire • 09/07/21
India Globalization Capital Receives Patent To Treat Alzheimer's With Cannabis DrugSeeking Alpha • 07/24/21